脊灰终止阶段经验对全球轮状病毒疫苗接种规划的启示
本文综述脊灰防控与消灭工作六十年进展,比较脊灰病毒与轮状病毒的相似性,讨论口服脊灰疫苗(OPV)与灭活脊灰疫苗(IPV)在消灭脊灰中的作用,并探讨将联合免疫策略应用于轮状病毒的潜力。近期科学证据确认IPV与OPV联合程序具有协同价值,可能为全球终止所有脊灰病毒传播提供工具;轮状病毒方面,口服疫苗是目前唯一获批推荐用于全球所有儿童的疫苗,而肠外轮状病毒疫苗处于临床前和临床试验阶段,脊灰经验为加速其开发提供有力依据。
要点
- OPV与IPV联合程序具协同价值,可能助力全球终止脊灰病毒传播。
- 口服轮状病毒疫苗是目前唯一获批推荐用于全球所有儿童的疫苗。
- 肠外轮状病毒疫苗尚处临床前和临床试验阶段,脊灰经验支持加速开发。
核心结论
- 脊灰防控经验支持加速开发肠外轮状病毒疫苗,口服与肠外联合使用或可提供必要体液和肠道免疫以缩小国家间效力差距。
研究设计与样本
- 综述,回顾脊灰预防与消灭工作六十年进展,并比较脊灰与轮状病毒防控策略。
主要发现
- OPV与IPV联合程序具协同价值,可能为全球终止脊灰病毒传播提供工具。
- 口服轮状病毒疫苗是目前唯一获批推荐用于全球所有儿童的疫苗,提供针对广泛毒株的异源保护。
- 肠外轮状病毒疫苗处于临床前和临床试验阶段。
临床怎么用
- 脊灰联合免疫策略的经验可用于指导轮状病毒疫苗规划,支持加速肠外轮状病毒疫苗开发。
- 口服与肠外轮状病毒疫苗联合使用或可缩小发展中国家与发达国家的效力差距,并可能降低肠套叠风险。
局限性
- 轮状病毒因动物宿主存在而不适于消灭。
- 口服疫苗在低收入地区存在安全关切和免疫应答欠佳的问题。
- 肠外轮状病毒疫苗需解决针对广泛毒株的保护等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Poliovirus and rotavirus share notable similarities. Although rotavirus is not amenable to eradication because of animal reservoirs, live, attenuated oral vaccines have been the bedrock of both prevention and control programs, providing intestinal and humoral immunity. Both programs have also encountered safety concerns and suboptimal immune responses to oral vaccines in low-income settings that have been challenges, prompting the search for alternative solutions. In this paper, we review the progress made by polio prevention and eradication efforts over the past six decades. Specifically, we discuss the roles of the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) in achieving polio eradication, and explore potential application of these lessons to rotavirus. Recent scientific evidence has confirmed that a combined schedule of IPV and OPV adds synergistic value that may give the polio eradication effort the tools to end all poliovirus circulation worldwide. For rotavirus, oral vaccine is the only currently licensed and recommended vaccine for use in all children worldwide, providing heterologous protection against a broad range of strains. However, parenteral rotavirus vaccines are in the pre-clinical and clinical trial stage and insight from polio provides strong justification for accelerating the development of these vaccines. While challenges for parenteral rotavirus vaccines will need to be addressed, such as achieving protection against a broad range of strains, the principle of combined use of oral and parenteral rotavirus vaccines may provide the necessary humoral and intestinal immunity necessary to close the efficacy gaps between developing and developed countries, therefore controlling rotavirus worldwide. This strategy may also potentially reduce risk of intussusception.
引用
- Jiang B, Patel M, Glass RI, et al. Polio endgame: Lessons for the global rotavirus vaccination program. Vaccine. 2019. PMID: 31027927. doi:10.1016/j.vaccine.2019.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。